Correlation of histamine-2 receptor antagonist (H2RA) and proton pump inhibitor (PPI) to the platelet count in patient with dengue viral infection

https://doi.org/10.19106/JMedSci005304202104

Riyadi Adrizain(1*), Maharani Simanjuntak(2), Andri Rezano(3)

(1) Department of Pediatrics, Faculty of Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung
(2) Faculty of Medicine, Universitas Padjadjaran
(3) Department of Biomedical Sciences, Division of Cell Biology, Faculty of Medicine, Universitas Padjadjaran, Bandung
(*) Corresponding Author

Abstract


Thrombocytopenia is often associated with clinically worse outcomes in dengue viral infection (DVI) patients. Histamine-2 receptor antagonist (H2RA) and proton pump inhibitor (PPI) have been reported to induce thrombocytopenia. These drugs are administered to DVI patients due to misinterpretation of abdominal pain. The study aimed to evaluate the correlation between H2RA and PPI administration with thrombocytopenia event on hospitalized DVI patients. An analytical retrospective cross-sectional study was conducted using medical records of the patient admitted by final diagnosed DVI in seven major hospital in Bandung from January 1st to December 31st, 2015. Patients were separated into two groups i.e. with and without H2RA and PPI. Pearson point biserial analysis was then applied to evaluate the correlation of each drug administration to platelet count of DVI.  A total of 4005 patients with final diagnosed DVI involved in this study. About 11.0% and 25.1% of the patients received H2RA and PPI, respectively. Mostly the DVI patients receiving H2RA (55%) and PPI (50.8%) showed the platelet count <50.000/mm3. A very weak positive correlation between the administration of H2RA (p <0.001; r=0.103) and PPI (p <0.001; r=0.138) with the low platelet count of the patients was observed. In conclusion, the administration of H2RA and PPI is correlated to the low platelet count in DVI patients. Although the correlation is weak, H2RA and PPI should be administered with caution due to its thrombocytopenia side effect.


Keywords


dengue viral infection; H2RA; PPI; thrombocytopenia; adverse event

Full Text:

PDF


References


  1. WHO. Comprehensive Guidelines for Preventing and Control of Dengue and Dengue Haemorrhagic Fever. World Health Organization-SEARO. 2011; 60:9-45.
  2. Pongpan S, Wisitwong A, Tawichasri C, Patumanond J. Prognostic indicators for dengue infection severity. Int J Clin Pediatr 2013; 2(1):12-8. https://doi.org/10.4021/ijcp73w
  3. Lam PK, Ngoc T Van, Thu Thuy TT, Hong Van NT, Nhu Thuy TT, Hoai Tam DT, et al. The value of daily platelet counts for predicting dengue shock syndrome: results from a prospective observational study of 2301 Vietnamese children with dengue. PLoS Negl Trop Dis 2017; 11(4):e0005498. https://doi.org/10.1371/journal.pntd.0005498
  4. Lee IK, Huang CH, Huang WC, Chen YC, Tsai CY, Chang K, et al. Prognostic factors in adult patients with dengue: developing risk scoring models and emphasizing factors associated with death ≤7 days after illness onset and ≤3 days after presentation. J Clin Med 2018; 7(11):396. https://doi.org/10.3390/jcm7110396
  5. Adrizain R, Setiabudi D, Chairulfatah A. Hospital-based surveillance: accuracy, adequacy, and timeliness of dengue case report in Bandung, West Java, Indonesia of 2015. J Glob Infect Dis 2018; 10(4):201-5. https://doi.org/10.4103/jgid.jgid_108_17
  6. Departemen Kesehatan RI. Sistem Kesehatan Nasional. Jakarta; 2009.
  7. Williamson DR, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Zarychanski R, et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: risk factors, and outcomes. Chest 2013; 144(4):1207-15. https://doi.org/10.1378/chest.13-0121
  8. Chawla P, Yadav A, Chawla V. Clinical implications and treatment of dengue. Asian Pac J Trop Med 2014; 7(3):169-78. https://doi.org/10.1016/S1995-7645(14)60016-X
  9. Dahlan SM. Hipotesis korelasi. In: Dahlan SM. 2014. Statistik untuk kedokteran dan kesehatan. 6th ed. Jakarta: Salemba Medika; 2014: 224–44.
  10. Kristin E, Yasmina A, Pinzon RT, Pratiwi WR, Trijayanti C, Setiawan E, Permanasari V, et al. Drug use pattern in dengue patients who visited hospitals and primary health center in Yogyakarta, Indonesia. J Pharm Sci Res 2018; 10(8):2065-8.
  11. Ojha A, Nandi D, Batra H, Singhal R, Annarapu GK, Bhattacharyya S, et al. Platelet activation determines the severity of thrombocytopenia in dengue infection. Sci Rep 2017; 7(41697):1-10. https://doi.org/10.1038/srep41697
  12. Goldthorpe SC, Conway MJ. New insight on dengue virus-induced thrombocytopenia. Virulence 2017; 8(8):1492-3. https://doi.org/10.1080/21505594.2017.1368943
  13. Gentilini G, Curtis BR, Aster RH. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. Blood 1998; 92(7):2359-65.
  14. Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, et al. Identifying drugs that cause acute thrombocytopenia: An analysis using 3 distinct methods. Blood 2010; 116(12):2127-33. https://doi.org/10.1182/blood-2010-03-276691
  15. Arnold DM, Kukaswadia S, Nazi I, Esmail A, Dewar L, Smith JW, et al. A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost 2013; 11(1):169-76. https://doi.org/10.1111/jth.12052
  16. Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost 2009; 7(6):911-8. https://doi.org/10.1111/j.1538-7836.2009.03360.x
  17. Kallam A, Singla A, Silberstein P. Proton pump induced thrombocytopenia: A case report and review of literature. Platelets 2015; 26(6):598-601. https://doi.org/10.3109/09537104.2014.953045
  18. Mukherjee S, Jana T, Pan J-J. Adverse effects of proton pump inhibitors on platelet count: a case report and review of the literature. Case Rep Gastrointest Med 2018; 2018:4294805. https://doi.org/10.1155/2018/4294805
  19. Fountain EM, Arepally GM. Etiology and complications of thrombocytopenia in hospitalized medical patients. J Thromb Thrombolysis 2017; 43(4):429-36. https://doi.org/10.1007/s11239-016-1467-8



DOI: https://doi.org/10.19106/JMedSci005304202104

Article Metrics

Abstract views : 2919 | views : 3186


Bookmark and Share


Copyright (c) 2021 Riyadi Adrizain, Maharani Simanjuntak, Andri Rezano

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.